Employer health plans brace for ongoing soaring costs as weight-loss drug utilization rises. What trends are coming down the ...

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

A recent Italian study reveals Mounjaro's effectiveness in maintaining weight loss over three years, particularly benefiting ...

Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

A retrospective study found that women who took a GLP-1 drug for obesity were more likely to be diagnosed with acne vulgaris ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

Robert F. Kennedy Jr. has given his first network television interview since becoming health secretary to Dr. Jon LaPook.

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for ...

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...